Analyst And Investor Information Update
5/23/2008
LONDON, UK, 23 May 2008 - Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, hosted an analyst and investor information update in London yesterday.
At the meeting, Jerome Sherman, OD, Eye Institute and Laser Center: New York, NY and Steven Schwartz, MD, Professor of ophthalmology and Chief of the Retina Division, Jules Stein Eye Institute, University of California at Los Angeles (UCLA) made presentations that illustrated how the introduction of Optos retinal imaging devices and technologies had transformed their work.
David J. Cairns, Optos' Chief Technical Officer, discussed the potential for future developments, including adaptive optics, which could extend the Company’s future reach further into the medical care market.
< ENDS >
Enquiries
|
Maitland |
+44 (0)20 7379 5151 |
|
Anne Wheeler |
|
|
Neil Bennett |
|
About Optos Plc
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos has commercialised a full range of complementary retinal imaging devices that support different customer segments and patient levels within the eye and healthcare market: P200 is concentrated on wellness screening carried out by optometrists and ophthalmologists; P200C in the advanced clinical optometry and ophthalmology markets; P200MA supports doctors through an advanced medical angiography procedure. All three devices provide practitioners with the benefit of an ultra wide-field high resolution view of the retina, facilitating the early detection, management and treatment of disorders and diseases evidenced in the retina such as glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.